Personal experience through two years with a trabecular micro-bypass stent during cataract surgery to manage IOP and reduce medication burden in patients with open-angle glaucoma (OAG) and cataract

Session Details

Session Title: Glaucoma II

Session Date/Time: Tuesday 08/09/2015 | 08:00-10:30

Paper Time: 08:06

Venue: Room 17

First Author: : R.Cionni USA

Co Author(s): :                        

Abstract Details

Purpose:

This goal of this work is to summarize personal experience through 2 years postoperative with use of a trabecular micro-bypass stent during cataract surgery to manage IOP and reduce topical ocular hypotensive medication burden in patients with open-angle glaucoma (OAG) and cataract.

Setting:

The Eye Institute of Utah and The Surgi-Care Center of Utah, USA

Methods:

Twenty nine eyes of 19 patients with OAG and cataract received one trabecular micro-bypass stent during cataract surgery and have been followed for up to 18 months. Demographics, best corrected visual acuity (BCVA), intraocular pressure (IOP), and medication use were assessed preoperatively. Postoperative assessments included BCVA, complications, IOP, and medication use. Data through two years postoperative from a larger series will be included.

Results:

There were 7 men and 12 women with mean age 74.6 (SD 12.2) years. Preoperatively, 69% had BCVA 20/40 or better. Mean IOP was 18.8 (SD 6.3) mmHg; 59% had IOP ≤ 18 mmHg. Eighty-three percent of eyes were on medication, including 28% on 3 medications. Postoperatively, BCVA was 20/40 or better in all eyes (20/25 or better in 82%). No device-related complications occurred. Mean IOP was 17.2 (SD 4.0) mmHg and 72% were on 0 medication; only 1 eye was on 3 medications. Ninety-three percent experienced reduction in IOP, reduction in medication, or reduction in both IOP and medication.

Conclusions:

Personal experience to implant a trabecular micro-bypass stent during cataract surgery in patients with OAG and cataract has shown substantial reduction in medication used preoperatively to control IOP. Over 90% of eyes were able to lower IOP and/or medication use, without complications typically associated with more invasive glaucoma surgery. The trabecular micro-bypass stent was found to be safe and effective in managing IOP while reducing medication burden.

Financial Interest:

One of the authors receives consulting fees, retainer, or contract payments from a competing company